The Menopause Benefit Market Is Running Into the CFO Problem

The menopause-at-work market is growing rapidly, but it is about to collide with a cold financial reality. As average employer health premiums climb past $18,500, CFOs are demanding proof of value over moral urgency. The real problem isn't low awareness—it is Tacere.

Menopause in the workplace has entered a different phase.

The benefits market is following the growth signal. Dedicated menopause benefits rose from 4% of U.S. employers in 2023 to 25% in 2026. But that market narrative is now colliding with a less convenient financial reality: employers are evaluating every new health benefit in a cost environment that demands proof of value.

Lozen Advisory’s market correction on menopause at work named the larger problem: the market has treated awareness as adoption, access as reach, and utilization as proof of need. The 2026 employer health-benefit cost environment makes that assumption harder to defend.

Rising Costs Are Changing the Conversation

Employers are not evaluating new benefits in a neutral budget cycle.

Mercer reported that average employer-sponsored health insurance cost reached $17,496 per employee in 2025, a 6.0% increase above inflation and wage growth, with another 6.7% increase expected in 2026. Prescription drug spending rose 9.4% among large employers. Mercer also reported that measuring health program performance is now a top three-to-five-year priority for more than three-quarters of large employers.

A menopause point solution does not arrive as a symbolic add-on in an unconstrained year. It arrives while employers are weighing pharmacy pressure, affordability concerns, and the value of every specialized program already in the portfolio. It has to withstand a performance question.

Low Utilization Is Not an Awareness Problem

The commercial case for menopause benefits is easy to understand. The affected population is large, the workforce impact is real, and employers have legitimate reasons to care about retention and continuity risk.

But menopause legislation and the market has moved faster than the measurement case. PwC noted that utilization remains limited and attributed this partly to employees not knowing the benefit exists. That explanation may be partly true. However, menopause benefits introduce a separate problem that awareness campaigns cannot solve.

A woman can know the benefit exists and still avoid it. She can need support and still decide that using it would create professional information she does not want her employer, manager, or vendor ecosystem to hold. That is not an education gap. It is a collection-condition problem, the structural condition Disclosure-Independent Governance℠ is built to classify: the governance architecture fails when the evidence base depends on a disclosure the affected population has decided not to make.

When an employee must search for a menopause resource, request leave, or use a menopause-coded pathway before the system can count her, the data point is created only after she decides to enter. When she does not enter, the data point is never generated.

The population most material to retention and succession risk may also be the population least likely to create that signal. Senior women have more authority to protect and less tolerance for being classified through a health-benefit pathway. Their non-use is not a communication failure. It is a decision. Lozen Advisory names this Tacere — the sustained, strategic practice of keeping one’s own counsel in a professional environment where disclosure carries professional cost.

The CFO Measurement Problem

The employer-facing pitch has expanded beyond care access. Employers are being sold a workforce-risk control package: a retention story, a productivity story, a legal and equity risk story, and a policy artifact the organization can announce.

That is why the market keeps moving even when utilization is weak. The product is not being sold only as healthcare, it is being sold as measurable reassurance.

Reassurance becomes fragile when the program still depends on an employee initiating access. The employer may buy a retention solution, the vendor may report participation, and the benefits team may point to program availability. None of those measures proves the benefit reached the population the purchase was meant to help.

The vendor measures users. The employer needs to understand the non-users. When the population most material to retention and succession risk is also the population most likely to avoid the pathway, the gap between those two groups is where the business case weakens and where the measurement system was never designed to look. That is the Disclosure-Independent Governance℠ gap.

Employer-Sellable vs. Employer-Measurable

Health-benefit costs are rising and employers are under pressure to measure program value. Menopause benefits are increasing. Yet utilization remains limited, and the architecture of most solutions still depends on employees initiating access in a category where initiation itself may carry professional cost.

Menopause benefits can still matter, and some women will use them, need them, and benefit from them. But employer value cannot be inferred from the existence of the offering, and utilization data cannot be treated as a proxy for population need.

The market has made menopause employer-sellable. It has not yet made menopause benefits employer-measurable. Until that changes, employers will be asked to finance access without proof of reach. In a cost-constrained health-benefit market, that is no longer a soft concern. It is the CFO problem.

Are Menopause Benefits Worth Investing In?

Menopause benefits may be worth investing in when the organization can prove more than access. Availability is not the same as adoption. Utilization is not the same as need.

The investment case is strongest when menopause benefits are evaluated alongside retention risk, leadership continuity, and the cost of non-use. A low-use benefit can still point to a real workforce problem, but it cannot be treated as evidence that the problem has been measured.

The market is measuring availability. CFOs need to measure exposure. The Retention Calculator estimates the replacement cost and fiscal exposure associated with senior leadership attrition, the number the benefits market is not giving you.